CONSOLIDATED, AMENDED AND RESTATED SENIOR SECURED CONVERTIBLE NOTEVitro Biopharma, Inc. • July 22nd, 2024 • Biological products, (no disgnostic substances) • Arizona
THIS SENIOR SECURED CONVERTIBLE NOTE is one of a series of duly authorized and validly issued Notes of Vitro Biopharma, Inc., a Nevada corporation (the “Company”), designated as its Senior Secured Convertible Note reflecting a 20% original issue discount (this note, this “Note” and, collectively with the other notes of such series, the “Notes”). This Note carries such original issue discount as indicated hereinabove.
Increase and Consolidation Amendment and Restatement of Senior Secured Convertible NotesVitro Biopharma, Inc. • July 22nd, 2024 • Biological products, (no disgnostic substances)
Reference is made to that certain: (A) Securities Purchase Agreement, dated as of November 16, 2023 (“Purchase Agreement”), as amended, between the undersigned Vitro Biopharma, Inc., a Nevada corporation (“Company”), and each purchaser identified on the Annex A thereto; (B) $2,500,000 Original Principal Amount Note Senior Secured Convertible Note dated November 16, 2023 (“First Note”) issued to you (“Holder”) thereunder; (C) $1,250,000 Original Principal Amount Note Senior Secured Convertible Note dated January 4, 2024 (collectively with the First Note, the “Outstanding Notes”) issued to you thereunder; and (D) letter agreement dated June 19, 2024 (captioned Extension of Senior Secured Convertible Note) (the “Prior Notes Amendment”) between the Company and Holder. Capitalized terms used herein but not defined herein shall have the meanings ascribed to such terms in the Purchase Agreement or Outstanding Notes, as applicable.
